Loading…
Loading…
BLLN (BillionToOne, Inc.) is a recent IPO.
It began trading on November 6, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates. The affected sections are flagged individually so you can tell limited history from missing data.
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) CEO Oguzhan Atay sold 5,150 shares of the business's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $100.23, for a total value of $516,184.50. Following the completion of the sale, the chief executive officer directly owned 3,183 shares of
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response
Shares of Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) were down 4.6% on Wednesday after an insider sold shares in the company. The stock traded as low as $112.75 and last traded at $112.72. 74,648 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 548,232 shares. The stock
The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.
The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.
The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.